No­var­tis makes a $1B ra­dio­phar­ma deal, buy­ing Mar­i­ana On­col­o­gy

No­var­tis will pay $1 bil­lion up­front to ac­quire ra­dio­phar­ma­ceu­ti­cal start­up Mar­i­ana On­col­o­gy, just eight months af­ter the pre­clin­i­cal biotech com­pa­ny dis­closed a $175 mil­lion Se­ries B.

The move, which could in­clude an­oth­er $750 mil­lion in mile­stones, fur­ther so­lid­i­fies the Swiss drug gi­ant’s em­brace of the red-hot field of ra­dio­phar­ma­ceu­ti­cals. No­var­tis mar­kets two such med­i­cines, Lu­tathera and Plu­vic­to, and just ear­li­er this week ex­pand­ed its ra­dio­phar­ma dis­cov­ery tie-up with Pep­tiDream.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER